[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100472038":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":36,"responsibleParty":54,"collaborators":11,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":11,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":11,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of Kentucky","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Glyburide treatment arm","EXPERIMENTAL",null,[13],"Drug: GlyBURIDE Oral Tablet",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","GlyBURIDE Oral Tablet","Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of spinal cord injury. The dosing regimen involves an initial dose of 1.25mg followed by 11 consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2, and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.\n\nIntervention: Drug: Glyburide",[9],[21],"Diabeta",[23],{"name":24,"affiliation":5,"role":25},"Francis Farhadi, MD, PhD","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"H. Francis Farhadi, MD, PhD","CONTACT","859-323-5661","francis.farhadi@uky.edu",{"name":33,"role":29,"phone":34,"phoneExt":11,"email":35},"Harshit Arora, PhD","859-323-4533","harshit.arora@uky.edu",[37],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Lexington","Kentucky","40536","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-84.47772,37.98869,{"lat":48,"lon":47},[51,53],{"name":24,"role":29,"phone":52,"phoneExt":11,"email":31},"859-562-0247",{"name":33,"role":29,"phone":34,"phoneExt":11,"email":35},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Francis Farhadi","Associate Professor of Neurosurgery","100472038","phase-1-spinal-cord-injury-neuroprotection-with-glyburide-100472038",false,"NCT05426681","Spinal Cord Injury Neuroprotection With Glyburide","Spinal Cord Injury Neuroprotection With Glyburide (SCING): Pilot Study: An Open-Label Prospective Evaluation of the Feasibility, Safety, Pharmacokinetics, and Preliminary Efficacy of Oral Glyburide (DiaBeta) in Patients With Acute Traumatic Spinal Cord Injury","SCING","Inclusion Criteria:\n\n* No life threatening injuries resulting from the traumatic accident\n* No evidence of sepsis\n* Acute cervical or thoracic SCI with ASIA Impairment Scale Grade A, B, or C od admission.\n* Non-penetrating SCI at neurologic level from C2 to C8 or T1 to T12\n\nExclusion Criteria:\n\n* Unconsciousness or other mental impairment that prevents neurological assessment within the first 8 hours\n* Acute SCI with ASIA Impairment Scale grade D or E\n* Currently involved in another non-observational SCI research study or receiving another investigational drug\n* History of hypersensitivity to sulfonylureas, in particular glyburide, or any of its components\n* Any condition likely to result in the patient's death within the next 12 months\n* Severe renal disorder from the patient's history (e.g. dialysis) or baseline eGFR of \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Known severe liver disease, or ALT \\> 3 times upper limit of normal or bilirubin\n* Blood glucose \\\u003C55 mg\u002FdL at enrollment or immediately prior to administration of DiaBeta, or a clinically significant history of hypoglycemia\n* Acute ST elevation myocardial infarction, and\u002For acute decompensated heart failure, and\u002For QTc \\> 520 ms, and\u002For known history of cardiac arrest (PEA, VT, VF, asystole), and\u002For admission for an acute coronary syndrome, myocardial infarction, or coronary intervention (percutaneous coronary intervention or coronary artery surgery) within the past 3 months\n* Known G6PD enzyme deficiency",true,"ALL","18 Years","80 Years",{"count":71,"type":72},12,"ESTIMATED","INTERVENTIONAL",[75],"PHASE1","To assess the safety and efficacy of using oral Glyburide (Diabeta) as a neuroprotective agent in patients with acute cervical or thoracic traumatic spinal cord injury.",[78],"Acute Spinal Cord Injury","2026-02-10",{"date":81,"type":82},"2026-02-13","ACTUAL",{"date":84,"type":82},"2022-07-07",{"date":86,"type":72},"2028-05",{"name":56,"class":6},1]